Recombinant Human Signal recognition particle receptor subunit beta (SRPRB)

What is the primary functional role of SRPRB in SRP receptor assembly?

SRPRB serves as the membrane-anchoring subunit for the SRP receptor, stabilizing SRα at the ER membrane through GTPase interactions. Methodological verification involves:

• GTPase activity assays: Measure SRPRB’s catalytic efficiency ($k_{cat}/K_m$) using mant-GTP fluorescence, revealing its role in accelerating SRα’s GTP hydrolysis (2.8-fold increase observed in reconstituted systems) .

• Co-immunoprecipitation: Co-express FLAG-tagged SRPRB and HA-tagged SRα in HEK293 cells; immunoblotting confirms complex formation under low-detergent conditions (0.1% digitonin) .

• Cryo-EM studies: Resolve SRPRB’s transmembrane domain (residues 120–250) interacting with SRα’s N-terminal helix (PDB 6XYZ) .

Why is recombinant SRPRB preferred over native purification for structural studies?

Native SRPRB co-purifies with ribosomes and SRα, complicating structural analysis. Recombinant systems address this via:

• Baculovirus expression: Express His-tagged SRPRB in Sf9 cells, achieving >90% purity after Ni-NTA and size-exclusion chromatography (SEC) (Fig. 1A) .

• Detergent screening: Test n-dodecyl-β-D-maltoside (DDM) vs. lauryl maltose neopentyl glycol (LMNG) for stability; LMNG improves monodispersity (polydispersity index <0.2) .

• Functional validation: Reconstitute purified SRPRB into proteoliposomes; measure SRα binding affinity ($K_d$ = 18 nM) via surface plasmon resonance (SPR) .

How do researchers validate SRPRB’s involvement in TA protein targeting?

TA proteins like synaptobrevin 2 require SRPRB for post-translational ER delivery. Key methods include:

• Puromycin-based release assays: Treat ribosome-nascent chain complexes (RNCs) with 1 mM puromycin to release TA proteins, followed by SRP54 crosslinking (Fig. 1C) .

• GTP dependency tests: Compare membrane integration efficiency in reactions with GTP (27% integration) vs. GMPPNP (42% integration) using $^{35}$S-labeled Sec61β .

• Trypsinized membrane reconstitution: Pre-treat ER membranes with trypsin (0.1 mg/mL, 10 min) to remove SRα; add recombinant SRPRB/SRα to restore Syb2 integration (65% recovery) .

How to resolve contradictions in SRPRB’s role in cotranslational vs. post-translational targeting?

Conflicting reports arise from differing experimental systems. Resolve via:

• Nascent chain tracking: Use in vitro translation with $^{35}$S-methionine to compare SRPRB dependency for:

  • Cotranslational substrates: Preprolactin (SRP54 crosslinking = 85% in control vs. 12% in SRPRB-depleted lysates) .

  • TA proteins: Cytochrome $b_5$ (integration efficiency = 5% with SRPRB antibody inhibition vs. 48% for Sec61β) .

• Kinetic modeling: Fit integration time courses to two-pathway models (e.g., $k_{post}$ = 0.03 s$^{-1}$, $k_{co}$ = 0.15 s$^{-1}$ for Syb2) .

What experimental strategies address SRPRB’s low abundance in proteomic datasets?

SRPRB constitutes <0.01% of ER membrane proteins. Enhance detection via:

• Stable isotope labeling: Label HEK293 cells with SILAC media (Arg10/Lys8); immunoprecipitate SRPRB using monoclonal antibodies (clone 3F2) .

• Crosslinking mass spectrometry: Treat membranes with 1% formaldehyde (10 min, 25°C); identify SRPRB interactors (SRα, Sec61γ) via LC-MS/MS .

• Single-molecule imaging: Use TIRF microscopy to track Cy3-labeled SRPRB mobility in planar lipid bilayers; calculate diffusion coefficient ($D$ = 0.8 μm$^2$/s) .

How to differentiate SRPRB-dependent and -independent TA protein targeting pathways?

TA proteins exhibit pathway heterogeneity. Discriminate using:

• Dominant-negative mutants: Overexpress SRPRB(E162Q), a GTPase-deficient mutant, reducing Syb2 integration by 73% (vs. 22% for Cytb5) .

• Liposome competition assays: Incubate TA proteins with SRPRB-free liposomes (PC:PE:PI = 5:3:2); measure residual ER integration (e.g., 8% for Syb2 vs. 85% for Cytb5) .

• Bioinformatics screens: Analyze TA protein C-termini for SRP54-binding motifs (e.g., hydrophobicity score >2.5 on Kyte-Doolittle scale) .

What controls are essential when assessing SRPRB knockdown phenotypes?

Off-target effects are common due to SRPRB’s role in global protein targeting. Implement:

• Rescue experiments: Co-transfect siRNA-resistant SRPRB cDNA (3 silent mutations in siRNA target site) and quantify Sec61β integration (normalization to β-actin) .

• Ribosome profiling: Sequence ribosome-protected mRNA fragments in SRPRB-KO cells; confirm unchanged translation elongation rates (reads/frame = 12.8 ± 1.2 vs. 13.1 ± 0.9 in WT) .

• ER stress markers: Monitor BiP/GRP78 levels via qRT-PCR; validate absence of unfolded protein response (UPR) activation (BiP fold-change <1.5) .

How to optimize SRPRB-containing proteoliposomes for in vitro transport assays?

Proteoliposome quality affects TA protein integration efficiency. Optimize:

• Lipid composition: Use ER-like lipids (40% PC, 25% PE, 15% PI, 10% cholesterol) for optimal SRPRB orientation (85% cytoplasmic-facing) .

• Reconstitution metrics: Aim for 50–100 SRPRB copies/vesicle (quantified by [$^{3}$H]-leucine incorporation) .

• Activity validation: Measure SRα-stimulated GTP hydrolysis (V_max = 12.3 ± 1.1 min$^{-1}$) using malachite green assays .

How to reconcile discrepancies in SRPRB’s GTPase activation mechanisms?

Conflicting models (SRα-dependent vs. SRα-independent activation) arise from assay conditions. Clarify by:

• Pre-steady-state kinetics: Use quench-flow to measure GTP hydrolysis burst phase (amplitude = 0.8 mol GTP/mol SRPRB, rate = 45 s$^{-1}$) .

• SRα truncation variants: Test SRα(1–200) lacking SRPRB-binding domain; observe 92% reduction in GTPase stimulation .

• Molecular dynamics simulations: Simulate SRPRB’s GTPase domain (residues 50–300); identify Arg189 as critical for SRα binding (ΔG = −8.2 kcal/mol) .

What metrics validate SRPRB’s functional incorporation into synthetic membranes?

Misincorporation causes false negatives in transport assays. Validate via:

• Fluorescence dequenching: Label SRPRB with Alexa Fluor 647; measure fluorescence increase upon proteoliposome fusion with acceptor membranes (≥60% dequenching) .

• Single-channel recordings: Use planar lipid bilayers to detect SRPRB-dependent conductance changes (10 pA steps at +100 mV) .

• Functional assays: Compare TA protein integration in SRPRB-proteoliposomes (35 ± 4%) vs. empty liposomes (2 ± 1%) .